One day after CSL suddenly replaced its CEO, the company provided dismal financial figures that helped explain why. In its half-year report, CSL said its net profit plummeted (PDF) from $2 billion in ...
After teasing a plasma-based manufacturing expansion in the U.S. late last year, CSL is putting in the work and firming up details behind the $1.5 billion project. Monday, the Australian biopharma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results